<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="edd9dcb2-c553-44a8-878e-61ad9642e2b5"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use nevanac safely and effectively. See full prescribing information for nevanac. 
nevanac (nepafenac)  suspension for ophthalmic use 
Initial U.S. Approval: 2005 
 
</title>
   <effectiveTime value="20110831"/>
   <setId root="52fe0332-388a-451c-b759-97e760883837"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="194123980" root="1.3.6.1.4.1.519.1"/>
            <name>Physicians Total Care, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="194123980" root="1.3.6.1.4.1.519.1"/>
                        <name>Physicians Total Care, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="relabel"/>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="repack"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="af995ae3-b03a-4478-9214-ba0106a24d56"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL listing data elements section"/>
               <effectiveTime value="20110831"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54868-6302" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Nevanac<suffix/>
                        </name>
                        <formCode code="C42994" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUSPENSION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>nepafenac</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="0065-0002" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="1" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0J9L7J6V8C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NEPAFENAC</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0J9L7J6V8C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NEPAFENAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="K61870Z308" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Y27PUL9H56" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TYLOXAPOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="3" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1">
                                       <translation code="C48477" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                                    </numerator>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="54868-6302-0" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20110831"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021862" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="193c4252-cd58-4ef7-afbb-ff15d313e5fc"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1  INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>NEVANAC<content styleCode="bold">
                        <sup>®</sup>
                     </content> 
ophthalmic suspension is indicated for the treatment of pain and inflammation 
associated with cataract surgery.</paragraph>
               </text>
               <effectiveTime value="20110831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>NEVANAC<sup>®</sup>
                           <content styleCode="bold"/>ophthalmic 
suspension is a nonsteroidal, anti-inflammatory prodrug indicated for the 
treatment of pain and inflammation associated with cataract surgery (<content styleCode="underline">
                              <linkHtml href="#section-2"> 1</linkHtml>
                           </content>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="38af4634-3e95-4b32-aa9f-01041610631e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2  DOSAGE AND ADMINISTRATION
</title>
               <text>
                  <paragraph>Enter section text here</paragraph>
               </text>
               <effectiveTime value="20110831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>One drop of NEVANAC<sup>®</sup> ophthalmic suspension 
should be applied to the affected eye(s) three-times-daily beginning 1 day prior 
to cataract surgery, continued on the day of surgery and through the first 2 
weeks of the postoperative period. (<content styleCode="underline">
                              <linkHtml href="#section-3"> 
2</linkHtml>
                           </content>)</paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="7aa84f84-ec52-4b33-b94e-dfbd70a9e798"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1  Recommended Dosing
</title>
                     <text>
                        <paragraph>One drop of NEVANAC<content styleCode="bold">
                              <sup>®</sup>
                           </content> should be applied to the affected eye(s) 
three-times-daily beginning 1 day prior to cataract surgery, continued on the 
day of surgery and through the first 2 weeks of the postoperative period.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="defb3543-1864-4e17-951d-bcda818f4fa7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2  Use with Other Topical Ophthalmic Medications
</title>
                     <text>
                        <paragraph>NEVANAC<content styleCode="bold">
                              <sup>®</sup>
                           </content> may be 
administered in conjunction with other topical ophthalmic medications such as 
beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and 
mydriatics.</paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="c420ad0b-82d6-4465-b295-722cd69aa08d"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3  DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>Sterile ophthalmic suspension: 0.1%</paragraph>
                  <paragraph>3 mL in a 4 mL bottle </paragraph>
               </text>
               <effectiveTime value="20110831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Sterile ophthalmic suspension: 0.1% (<content styleCode="underline">
                              <linkHtml href="#section-4"> 3</linkHtml>
                           </content>)</paragraph>
                        <paragraph>3 mL in a 4 mL bottle</paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="d2776dea-e310-49ba-9a7e-79e579253137"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4  CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>NEVANAC<content styleCode="bold">
                        <sup>®</sup>
                     </content> is 
contraindicated in patients with previously demonstrated hypersensitivity to any 
of the ingredients in the formula or to other NSAIDs.</paragraph>
               </text>
               <effectiveTime value="20110831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity to any of the ingredients in the formula or to 
other NSAIDS.(<content styleCode="underline">
                              <linkHtml href="#section-5"> 4</linkHtml>
                           </content>)</paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="696b46de-04af-4fd4-9d7d-94623263e3a1"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5  WARNINGS AND PRECAUTIONS
</title>
               <text>
                  <paragraph>Enter section text here</paragraph>
               </text>
               <effectiveTime value="20110831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Increased bleeding time due to increased thrombocyte aggregation 
(<content styleCode="underline">
                              <linkHtml href="#section-6.1"> 5.1</linkHtml>
                           </content>)</paragraph>
                        <paragraph>Delayed healing (<content styleCode="underline">
                              <linkHtml href="#section-6.2"> 
5.2</linkHtml>
                           </content>) </paragraph>
                        <paragraph>Corneal effects including keratitis (<content styleCode="underline">
                              <linkHtml href="#section-6.3"> 5.3</linkHtml>
                           </content>)</paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="6381a96c-74b4-4dd1-951b-713917dc97e8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1  Increased Bleeding Time
</title>
                     <text>
                        <paragraph>With some nonsteroidal anti-inflammatory drugs including 
NEVANAC<content styleCode="bold">
                              <sup>®</sup>
                           </content>, there exists the 
potential for increased bleeding time due to interference with thrombocyte 
aggregation. There have been reports that ocularly applied nonsteroidal 
anti-inflammatory drugs may cause increased bleeding of ocular tissues 
(including hyphemas) in conjunction with ocular surgery.</paragraph>
                        <paragraph>It is recommended that NEVANAC<content styleCode="bold">
                              <sup>® 
</sup>
                           </content>ophthalmic suspension be used with caution in patients with known 
bleeding tendencies or who are receiving other medications which may prolong 
bleeding time.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e0e675b7-fe3d-4ae4-9fd6-a2bc4e9e9b82"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2  Delayed Healing
</title>
                     <text>
                        <paragraph>Topical nonsteroidal anti-inflammatory drugs (NSAIDs) including 
NEVANAC<content styleCode="bold">
                              <sup>®</sup>
                           </content>, may slow or delay 
healing. Topical corticosteroids are also known to slow or delay healing. 
Concomitant use of topical NSAIDs and topical steroids may increase the 
potential for healing problems.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="9e05373f-5716-49c6-b7c3-457cfc42d6b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3  Corneal Effects
</title>
                     <text>
                        <paragraph>Use of topical NSAIDs may result in keratitis. In some 
susceptible patients, continued use of topical NSAIDs may result in epithelial 
breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal 
perforation. These events may be sight threatening. Patients with evidence of 
corneal epithelial breakdown should immediately discontinue use of topical 
NSAIDs including NEVANAC<content styleCode="bold">
                              <sup>®</sup>
                           </content> and 
should be closely monitored for corneal health.</paragraph>
                        <paragraph>Postmarketing experience with topical NSAIDs suggests that patients with 
complicated ocular surgeries, corneal denervation, corneal epithelial defects, 
diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid 
arthritis, or repeat ocular surgeries within a short period of time may be at 
increased risk for corneal adverse events which may become sight threatening. 
Topical NSAIDs should be used with caution in these patients.</paragraph>
                        <paragraph>Postmarketing experience with topical NSAIDs also suggests that use more than 
1 day prior to surgery or use beyond 14 days post surgery may increase patient 
risk and severity of corneal adverse events.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d2b16758-feb3-466a-9971-4ab830e1210a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4  Contact Lens Wear
</title>
                     <text>
                        <paragraph>NEVANAC<content styleCode="bold">
                              <sup>®</sup>
                           </content> should 
not be administered while using contact lenses.</paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="82ae687e-5830-4aca-abb0-59fb75abf01e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6  ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>Because clinical studies are conducted under widely varying 
conditions, adverse reaction rates observed in the clinical studies of a drug 
cannot be directly compared to the rates in the clinical studies of another drug 
and may not reflect the rates observed in practice.</paragraph>
               </text>
               <effectiveTime value="20110831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (5 to 10%) are capsular</paragraph>
                        <paragraph>opacity, decreased visual acuity, foreign body sensation, increased 
intraocular pressure, and sticky sensation. (<content styleCode="underline">
                              <linkHtml href="#section-">  6.1</linkHtml>
                           </content>)</paragraph>
                        <br/>
                        <paragraph>
                           <br/>
                        </paragraph>
                        <paragraph>To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc. at 
1-800-757-9195 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                           <br/>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="8d5318a7-3c08-4fe4-988f-d210719e7afa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1  Ocular Adverse Reactions
</title>
                     <text>
                        <paragraph>The most frequently reported ocular adverse events following 
cataract surgery were capsular opacity, decreased visual acuity, foreign body 
sensation, increased intraocular pressure, and sticky sensation. These events 
occurred in approximately 5 to 10% of patients.</paragraph>
                        <paragraph>Other ocular adverse events occurring at an incidence of approximately 1 to 
5% included conjunctival edema, corneal edema, dry eye, lid margin crusting, 
ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, photophobia, 
tearing and vitreous detachment.</paragraph>
                        <paragraph>Some of these events may be the consequence of the cataract surgical 
procedure.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f7350b73-3eb7-431f-a356-b15e5ffe8563"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2  Non-Ocular Adverse Reactions
</title>
                     <text>
                        <paragraph>Non-ocular adverse events reported at an incidence of 1 to 4% 
included headache, hypertension, nausea/vomiting, and sinusitis.</paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="64d4c019-36cc-46af-b5fb-ac3a4c11b671"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8  USE IN SPECIFIC POPULATIONS
</title>
               <text>
                  <paragraph>Enter section text here</paragraph>
               </text>
               <effectiveTime value="20110831"/>
               <component>
                  <section>
                     <id root="f212d37e-c627-4941-a863-1e6e5ae5e4c5"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1  Pregnancy
</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Teratogenic Effects. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Pregnancy Category C: </content>Reproduction studies performed 
with nepafenac in rabbits and rats at oral doses up to 10 mg/kg/day have 
revealed no evidence of teratogenicity due to nepafenac, despite the induction 
of maternal toxicity. At this dose, the animal plasma exposure to nepafenac and 
amfenac was approximately 260 and 2400 times human plasma exposure at the 
recommended human topical ophthalmic dose for rats and 80 and 680 times human 
plasma exposure for rabbits, respectively. In rats, maternally toxic doses ≥ 10 
mg/kg were associated with dystocia, increased postimplantation loss, reduced 
fetal weights and growth, and reduced fetal survival. </paragraph>
                        <paragraph>Nepafenac has been shown to cross the placental barrier in rats. There are no 
adequate and well-controlled studies in pregnant women. Because animal 
reproduction studies are not always predictive of human response, NEVANAC<content styleCode="bold">
                              <sup>®</sup>
                           </content> should be used during pregnancy only 
if the potential benefit justifies the potential risk to the fetus.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Non-teratogenic Effects.</content>
                        </paragraph>
                        <paragraph>Because of the known effects of prostaglandin biosynthesis inhibiting drugs 
on the fetal cardiovascular system (closure of the ductus arteriosus), the use 
of NEVANAC<sup>® </sup>during late pregnancy should be avoided.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f91946c9-2741-4dfd-a433-429b5e6d6779"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3  Nursing Mothers
</title>
                     <text>
                        <paragraph>NEVANAC<content styleCode="bold">
                              <sup>®</sup>
                           </content> is 
excreted in the milk of lactating rats. It is not known whether this drug is 
excreted in human milk. Because many drugs are excreted in human milk, caution 
should be exercised when NEVANAC<content styleCode="bold">
                              <sup>®</sup>
                           </content> 
ophthalmic suspension is administered to a nursing woman.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2b1d5f2f-1206-4e4d-a870-c1b3b8f74505"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4  Pediatric Use
</title>
                     <text>
                        <paragraph>The safety and effectiveness of NEVANAC<content styleCode="bold">
                              <sup>®</sup>
                           </content> in pediatric patients below the age of 10 years have 
not been established.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="1b36b1cd-1d06-4e5f-84b6-e511d47ab282"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5  Geriatric Use
</title>
                     <text>
                        <paragraph>No overall differences in safety and effectiveness have been 
observed between elderly and younger patients.</paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="61730f09-06b0-42d1-b42b-664c2ba0c613"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11  DESCRIPTION
</title>
               <text>
                  <paragraph>NEVANAC<content styleCode="bold">
                        <sup>®</sup>
                     </content> 
(nepafenac ophthalmic suspension) 0.1% is a sterile, topical, nonsteroidal 
anti-inflammatory (NSAID) prodrug for ophthalmic use. Each mL of NEVANAC<content styleCode="bold">
                        <sup>®</sup>
                     </content> suspension contains 1 mg of 
nepafenac. Nepafenac is designated chemically as 
2-amino-3-benzoylbenzeneacetamide with an empirical formula of C<sub>15</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>. The structural formula of nepafenac is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Nepafenac is a yellow crystalline powder. The molecular weight of nepafenac 
is 254.28. NEVANAC<content styleCode="bold">
                        <sup>®</sup>
                     </content>ophthalmic 
suspension is supplied as a sterile, aqueous 0.1% suspension with a pH 
approximately of 7.4. </paragraph>
                  <paragraph>The osmolality of NEVANAC<content styleCode="bold">
                        <sup>®</sup>
                     </content>ophthalmic suspension is approximately 305 mOsmol/kg. 
</paragraph>
                  <paragraph>Each mL of NEVANAC<content styleCode="bold">
                        <sup>® </sup>
                     </content>contains: 
Active: nepafenac 0.1% Inactives: mannitol, carbomer 974P, sodium chloride, 
tyloxapol, edetate disodium, benzalkonium chloride 0.005% (preservative), sodium 
hydroxide and/or hydrochloric acid to adjust pH and purified water, USP.</paragraph>
               </text>
               <effectiveTime value="20110831"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM1">
                     <text>image of structural formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="nevanac-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="c854a8d8-abb1-479c-a7af-c2d4d87935f0"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12  CLINICAL PHARMACOLOGY
</title>
               <text>
                  <paragraph>Enter section text here</paragraph>
               </text>
               <effectiveTime value="20110831"/>
               <component>
                  <section>
                     <id root="4360b35d-5977-4297-9236-019367c26881"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1  Mechanism of Action
</title>
                     <text>
                        <paragraph>After topical ocular dosing, nepafenac penetrates the cornea and 
is converted by ocular tissue hydrolases to amfenac, a nonsteroidal 
anti-inflammatory drug. Amfenac is thought to inhibit the action of 
prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin 
production.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="a7c06108-7efd-45fa-9c7d-568cdadec9c6"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3  Pharmacokinetics
</title>
                     <text>
                        <paragraph>Low but quantifiable plasma concentrations of nepafenac and 
amfenac were observed in the majority of subjects 2 and 3 hours postdose, 
respectively, following bilateral topical ocular three-times-daily dosing of 
nepafenac ophthalmic suspension, 0.1%. The mean steady-state C<sub>max</sub> for nepafenac and for amfenac were 0.310 ± 0.104 ng/ml and 
0.422 ± 0.121 ng/ml, respectively, following ocular administration.</paragraph>
                        <paragraph>Nepafenac at concentrations up to 300 ng/mL did not inhibit the <content styleCode="italics">in vitro </content>metabolism of 6 specific marker substrates of 
cytochrome P450 (CYP) isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and 
CYP3A4). Therefore, drug-drug interactions involving CYP mediated metabolism of 
concomitantly administered drugs are unlikely. Drug-drug interactions mediated 
by protein binding are also unlikely. </paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="e0dbbfd9-763e-441e-830f-e71b08c88afb"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13  NONCLINICAL TOXICOLOGY
</title>
               <text>
                  <paragraph>Enter section text here</paragraph>
               </text>
               <effectiveTime value="20110831"/>
               <component>
                  <section>
                     <id root="ddcefdf9-2b85-4db1-bfb9-ced2cc8a5510"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility
</title>
                     <text>
                        <paragraph>Nepafenac has not been evaluated in long-term carcinogenicity 
studies. Increased chromosomal aberrations were observed in Chinese hamster 
ovary cells exposed <content styleCode="italics">in vitro </content>to nepafenac suspension. 
Nepafenac was not mutagenic in the Ames assay or in the mouse lymphoma forward 
mutation assay. Oral doses up to 5,000 mg/kg did not result in an increase in 
the formation of micronucleated polychromatic erythrocytes <content styleCode="italics">in vivo </content>in the mouse micronucleus assay in the bone marrow 
of mice.</paragraph>
                        <paragraph>Nepafenac did not impair fertility when administered orally to male and 
female rats at 3 mg/kg (approximately 90 and 380 times the plasma exposure to 
the parent drug, nepafenac, and the active metabolite, amfenac, respectively, at 
the recommended human topical ophthalmic dose).</paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="30368bf7-70fd-45bb-b1d0-088dff8d60ae"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14  CLINICAL STUDIES
</title>
               <text>
                  <paragraph>In two double-masked, randomized clinical trials in which 
patients were dosed three-times-daily beginning one day prior to cataract 
surgery, continued on the day of surgery and for the first two weeks of the 
postoperative period, NEVANAC<sup>®</sup> ophthalmic suspension 
demonstrated clinical efficacy, compared to its vehicle in treating 
postoperative inflammation.</paragraph>
                  <paragraph>Patients treated with NEVANAC<sup>®</sup> ophthalmic suspension 
were less likely to have ocular pain and measurable signs of inflammation (cells 
and flare) in the early postoperative period through the end of treatment than 
those treated with its vehicle.</paragraph>
                  <paragraph>For ocular pain in both studies a significantly higher percentage of patients 
(approximately 80%) in the nepafenac group reported no ocular pain on the day 
following cataract surgery (Day 1) compared to those in the vehicle group 
(approximately 50%).</paragraph>
                  <paragraph>Results from clinical studies indicated that NEVANAC<content styleCode="bold">
                        <sup>® </sup>
                     </content>has no significant effect upon intraocular pressure; 
however, changes in intraocular pressure may occur following cataract 
surgery.</paragraph>
               </text>
               <effectiveTime value="20110831"/>
            </section>
         </component>
         <component>
            <section>
               <id root="433f14b7-32fd-41e8-9a37-a83dff6cf02c"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16  HOW SUPPIED/STORAGE AND HANDLING
</title>
               <text>
                  <paragraph>NEVANAC<content styleCode="bold">
                        <sup>®</sup>
                     </content> 
(nepafenac ophthalmic suspension) is supplied in a natural, oval, low density 
polyethylene DROP-TAINER® dispenser with a natural low density polyethylene 
dispensing plug and gray polypropylene cap. Tamper evidence is provided with a 
shrink band around the closure and neck area of the package.</paragraph>
                  <paragraph>3 mL in 4 mL bottle      NDC 54868-6302-0<br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage: </content>Store at 2 - 25°C (36 - 77°F).</paragraph>
               </text>
               <effectiveTime value="20110831"/>
            </section>
         </component>
         <component>
            <section>
               <id root="fa3a3969-a4d1-4578-8b38-dcf2a61b5908"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17  PATIENT COUNSELING INFORMATION
</title>
               <text>
                  <paragraph>Enter section text here</paragraph>
               </text>
               <effectiveTime value="20110831"/>
               <component>
                  <section>
                     <id root="157376e6-40e1-4e78-9485-ca2918e0d77c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.1  Slow or Delayed Healing
</title>
                     <text>
                        <paragraph>Patients should be informed of the possibility that slow or 
delayed healing may occur while using nonsteroidal anti-inflammatory drugs 
(NSAIDs).</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="a62786ad-25d7-41d9-a244-aee182bb13f4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.2  Avoiding Contamination of the Product
</title>
                     <text>
                        <paragraph>Patients should be instructed to avoid allowing the tip of the 
dispensing container to contact the eye or surrounding structures because this 
could cause the tip to become contaminated by common bacteria known to cause 
ocular infections. Serious damage to the eye and subsequent loss of vision may 
result from using contaminated solutions.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="4407cf5a-2b56-40ad-a7f2-b18500e313fd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.3  Contact Lens Wear
</title>
                     <text>
                        <paragraph>NEVANAC<sup>® </sup>should not be administered while 
wearing contact lens.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0234277b-6a70-4655-8e91-f967b41b9e32"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.4  Intercurrent Ocular Conditions
</title>
                     <text>
                        <paragraph>Patients should be advised that if they develop an intercurrent 
ocular condition (e.g., trauma, or infection) or have ocular surgery, they 
should immediately seek their physician's advice concerning the continued use of 
the multi-dose container.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0ee5f180-1614-4b15-8b13-bd293d01aa1f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.5  Concomitant Topical Ocular Therapy
</title>
                     <text>
                        <paragraph>If more than one topical ophthalmic medication is being used, the 
medicines must be administered at least 5 minutes apart.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="a850dbd8-9d70-4943-a626-5221357e8d7f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.6 Shake Well Before Use
</title>
                     <text>
                        <paragraph>Patients should be advised to shake the bottle well.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="6ab61ade-50b2-4a7d-b041-113d8cabc0ba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>U.S. Patent No; 5,475,034</paragraph>
                        <paragraph>
                           <content styleCode="bold">ALCON</content>®</paragraph>
                        <paragraph>ALCON LABORATORIES, INC.</paragraph>
                        <paragraph>Fort Worth, Texas 76134 USA</paragraph>
                        <paragraph>© 2007 Alcon, Inc.</paragraph>
                        <linkHtml href=""/>
                        <br/>
                        <br/>
                        <content styleCode="bold">Additional barcode labeling by:</content>
                        <br/>Physicians Total Care, Inc.<br/>Tulsa, OK     74146<br/>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="02fbc69c-3422-49dd-8b07-a36afd74092f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NEVANAC<content styleCode="bold">
                        <sup>®</sup>
                     </content> (nepafenac ophthalmic 
suspension)</paragraph>NDC 54868-6302-0<br/>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM2"/>
                  </paragraph>
                  <paragraph>3 mL<br/>
                  </paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20110831"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM2">
                     <text>image of package label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="6302.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>